<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310917</url>
  </required_header>
  <id_info>
    <org_study_id>2020/CHU/01</org_study_id>
    <nct_id>NCT04310917</nct_id>
  </id_info>
  <brief_title>Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island</brief_title>
  <acronym>COLLIPAR</acronym>
  <official_title>Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease (CVD) is the second leading cause of death in France and the leading&#xD;
      cause of death on Reunion Island. Some modifiable risk factors for cardiovascular diseases&#xD;
      are well identified and can be easily modulated, in particular by hygiene and dietetic&#xD;
      measures (tobacco, sedentary lifestyle). Other risk factors such as high blood pressure,&#xD;
      diabetes or dyslipidemia can also be pharmacologically modulated. On the other hand, there is&#xD;
      a cardiovascular risk factor that we do not know how to modulate: a high level of lipoprotein&#xD;
      (a) (Lp (a)), whose regulation remains largely unknown.&#xD;
&#xD;
      High plasma levels of Lipoprotein (a) remain a major risk for the development of&#xD;
      cardiovascular disease and its clinical complications, which no drug can currently reduce.&#xD;
      Understanding the biological and genetic determinants modulating Lp (a) levels remains a&#xD;
      major challenge for treating subjects with hyper Lp (a). Several individuals and possibly&#xD;
      Reunion families have been detected as having abnormally high rates of apo (a)&#xD;
&#xD;
      Thanks to the link between cardiovascular clinical picture, Lp (a) concentration and other&#xD;
      biological markers, the study should allow a better understanding of the mechanisms&#xD;
      underlying the cardiovascular risk in order to offer advice. prevention and care of at-risk&#xD;
      subjects screened; or even avenues for adapted genetic counseling (DNA sequencing).&#xD;
&#xD;
      At the genetic level, several hypotheses could be explored making it possible to link the&#xD;
      expression of the apo (a) protein to the genotype, in particular the presence of mutations in&#xD;
      the gene, in the promoter region, polymorphisms, or epistatic regulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carry out a family screening of the plasma Lp (a) level</measure>
    <time_frame>at inclusion</time_frame>
    <description>Carry out a family screening of the plasma Lp (a) level around index cases followed or directed towards Reunion University Hospital (index case = Lp (a) rate&gt; 200nmol / L)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Lipoprotein a level</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood lipoprotein (a) test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood lipoprotein (a) test</intervention_name>
    <description>research specific blood sample</description>
    <arm_group_label>Lipoprotein a level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with Lp (a)&gt; 200 nmol / L OR member of family of a patient with Lp (a)&gt; 200&#xD;
             nmol / L&#xD;
&#xD;
          -  be affiliated or beneficiary of a social security scheme&#xD;
&#xD;
          -  signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya KHANTALIN, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de la Réunion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucie AUZANNEAU</last_name>
    <phone>0262359949</phone>
    <phone_ext>+262</phone_ext>
    <email>lucie.auzanneau@chu-reunion.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de la Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie AUZANNEAU</last_name>
    </contact>
    <investigator>
      <last_name>Ilya KHANTALIN, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

